Pemetrexed approved for use in first-line treatment of most common lung cancer

  • Editorial Office


Johannesburg, 7 October 2009:

Lilly today announced that their pemetrexed for injection has been approved for a histologically- based use in the first-line treatment of advanced non-small-cell lung cancer (NSCLC)1, the most common form of lung cancer2.
Press Releases